Although various factors (such as vascular endothelial growth factor [VEGF], insulin-like growth factor 1, platelet-derived growth factor [PDGF], human epidermal growth factor receptor 2, and hepatocyte growth factor receptor [MET]) overexpressed in osteosarcoma tumour cells have been suggested as therapeutic targets [10], no targeted agents, including kinase inhibitors, have yet been approved for this condition. This evidence concerns the gene MET and osteosarcoma.